Treatment demonstrated a good safety profile in the overall patient population during the 12-week induction phase
Moderna CEO Bancel set for a soft landing as his golden parachute swells to $926M kdunleavy Fri, 03/11/2022 […]
Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profits […]
BeiGene, Hutchmed, Zai Lab tagged for potential US delisting under SEC audit rules, with more Chinese biotechs likely […]
Fierce Pharma Asia—Legend CEO’s cell therapy ambitions; Indian pharmas’ awkward position; new Hutchmed CEO aliu Fri, 03/11/2022 – […]
Calculating a person’s risk of developing prostate cancer using results from two blood markers would improve the accuracy […]
Skoltech researchers and their colleagues from HSE University and York University have presented an extensive dataset of indices […]
Listen“Listen to the patient; he is telling you the diagnosis.” I should be surprised if this aphorism has […]
The covid-19 pandemic has been exacerbated by underinvestment in public health, an “infodemic” of false or misleading information, […]
93% of people suspected by GPs to have cancer should be seen by a specialist within two weeks […]